Steward Partners Investment Advisory LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 11.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,159 shares of the medical research company's stock after selling 9,963 shares during the quarter. Steward Partners Investment Advisory LLC's holdings in Amgen were worth $19,589,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the stock. Gryphon Financial Partners LLC boosted its position in shares of Amgen by 5.8% during the 4th quarter. Gryphon Financial Partners LLC now owns 4,475 shares of the medical research company's stock worth $1,166,000 after purchasing an additional 245 shares in the last quarter. Silver Coast Investments LLC increased its position in Amgen by 5.4% in the 4th quarter. Silver Coast Investments LLC now owns 935 shares of the medical research company's stock valued at $244,000 after buying an additional 48 shares in the last quarter. Auxano Advisors LLC raised its stake in Amgen by 2.7% during the 4th quarter. Auxano Advisors LLC now owns 2,578 shares of the medical research company's stock worth $672,000 after buying an additional 68 shares during the period. Woodley Farra Manion Portfolio Management Inc. boosted its holdings in Amgen by 2.7% in the fourth quarter. Woodley Farra Manion Portfolio Management Inc. now owns 14,126 shares of the medical research company's stock worth $3,682,000 after acquiring an additional 371 shares in the last quarter. Finally, Fidelis Capital Partners LLC grew its stake in Amgen by 3.6% in the fourth quarter. Fidelis Capital Partners LLC now owns 4,609 shares of the medical research company's stock valued at $1,331,000 after acquiring an additional 160 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on AMGN shares. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Citigroup reiterated a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Piper Sandler Companies reissued an "overweight" rating and set a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Finally, William Blair restated an "outperform" rating on shares of Amgen in a report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $314.09.
Read Our Latest Research Report on AMGN
Amgen Stock Performance
Shares of NASDAQ AMGN traded up $1.41 during midday trading on Tuesday, hitting $312.19. The company's stock had a trading volume of 3,819,193 shares, compared to its average volume of 2,546,395. The firm has a market capitalization of $167.71 billion, a price-to-earnings ratio of 41.35, a P/E/G ratio of 2.63 and a beta of 0.56. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock has a fifty day moving average price of $281.80 and a 200 day moving average price of $299.73. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.
Amgen Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.05%. Amgen's dividend payout ratio is presently 126.09%.
Insider Transactions at Amgen
In other news, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David M. Reese sold 8,711 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total value of $2,554,239.42. Following the completion of the sale, the executive vice president now owns 62,147 shares in the company, valued at $18,222,743.34. This trade represents a 12.29 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is currently owned by corporate insiders.
About Amgen
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
